



FRENCH GLIOBLASTOMA BIOBANK

FGB

jan 2019

Scientific context

Malignant tumors of the central nervous system represent a public health issue because of their increasing incidence, their often incurable nature and the morbidity they generate. This project focuses on glioblastoma (GB) because they are the most frequent and most aggressive primary malignant brain tumors; they

have a well-standardized treatment, at least on first line, that permit to build a relatively homogeneous cohort. Moreover, their poor prognosis makes it possible to have a complete follow-up in a few years.

A French national biological and clinical database approved by all the national regulatory authorities

Access to data

Research project promoter wishing to use our resources must complete a request form, available on request to Prof. Menei

Projects are submitted for acceptance to the Consortium Scientific Committee and the decision is forwarded to project promoter within 21 calendar days of submission.

The delay for the provision of the biological samples is currently 4 months.

Different types of contracts are available.

Please contact us for more details

Contacts



Coordinator :

- **Pr Menei P**
Neurosurgeon,
CHU Angers
phmenei@chu-angers.fr

Co-coordinators :

- **Pr Figarella-Branger D**
Neuropathologist
AP-HM Marseille

- **Dr Bauchet L**
Neurosurgeon
CHU Montpellier

Research Assistant :

- **Mrs Soulard G**
CRA
CHU Angers
gwsoulard@chu-angers.fr

Links



<https://epidemiologie-france.aviesan.fr/epidemiologie-france/fiches/french-glioblastoma-biobank>

<http://www.biobanques.eu/fr/annuaire-des-biobanques/item/bcb-glioblastomes>
<http://lesdonnees.e-cancer.fr/Projets-de-Recherche/Base-de-donnees-Clinicobiologique-de-Glioblastomes>

https://directory.bbmri-eric.eu/menu/main/dataexplorer/details/eu_bbmri_eric_collections/bbmri-eric:ID:FR_BB-0033-00093:collection:mainCollection

https://www.linkedin.com/feed/?lipi=urn%3Ali%3Apage%3Ad_flagship3_company%3B58tE9YJSCm09FmWglCryw%3D%3D

Data from 1100 patients included in France
Cohort of interest available (young, long or short survival, family history or recurrence)

Samples before radio-chemotherapy (pre and postoperative) are stored in certified Biological Resources Centers

Biological samples	Specimen collection	Volume of samples per patient
Tumor tissue	Freezing in liquid nitrogen	3 samples (one for stereotactic biopsy)
	Human albumin/DMSO (liquid nitrogen)	3 samples Coming for 2018
	FFPE tissue block (room temperature)	1 block
Peri-tumoral tissue Coming for 2018	Freezing in liquid nitrogen	3 samples
	FFPE tissue block (room temperature)	1 block
Blood	Whole blood (-80°C)	1 mL
	Plasma (-80°C)	4 aliquots of 500 µL
	Serum (-80°C)	4 aliquots of 1 mL
	Buffy coat (-80°C)	2 aliquots of de 250 µL
Hair		A lock

Traceability all along the preparation process of samples

Clinical data in a secured eDatabase: (Clinsight, Ennov clinical- <http://en.ennov.com/>)

- ✓ Preoperative clinical and radiological data (medical history, toxic exposure and family history of tumors, tumor localization, MRI)
- ✓ Data from surgery (excision or biopsy, macroscopically complete, partial excision, histologic and molecular analysis of the tumor)
- ✓ Postoperative data every 6 months (radio chemotherapy lines and responses to treatments)
- ✓ Vital status

Partners

- INCa (<https://www.e-cancer.fr/Professionnels-de-la-recherche/Recherche-translationnelle/Les-BCB>)
- University Hospital of Angers
- Réseau de relecture anatomopathologique RENOCLIP (Pr Figarella-Branger)
- Réseau national histologique des tumeurs du système nerveux central (RnhTPSNC)
- ANOCEF/IGCNO (<https://www.anocef.org/>)
- Société Française de Neurochirurgie (<http://www.neurochirurgie.fr/>)
- Société Française de Neurologie (<https://www.sf-neuro.org/>)
- Société Française de Neuropathologie
- BIOBANQUES (<http://www.biobanques.eu/fr/>)
- BBMRI-ERIC (<http://www.bbmri-eric.eu/>)